AB Stock Overview
A clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
AB Science S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.82 |
| 52 Week High | €4.47 |
| 52 Week Low | €0.80 |
| Beta | 1.19 |
| 11 Month Change | -14.91% |
| 3 Month Change | -16.12% |
| 1 Year Change | -71.11% |
| 33 Year Change | -93.27% |
| 5 Year Change | -84.43% |
| Change since IPO | -93.52% |
Recent News & Updates
Shareholder Returns
| AB | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | -7.7% | -3.4% | -0.3% |
| 1Y | -71.1% | 6.2% | -3.5% |
Return vs Industry: AB underperformed the French Pharmaceuticals industry which returned 6.2% over the past year.
Return vs Market: AB underperformed the French Market which returned -2.5% over the past year.
Price Volatility
| AB volatility | |
|---|---|
| AB Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: AB has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: AB's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 40 | Alain Moussy | www.ab-science.com |
AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia.
AB Science S.A. Fundamentals Summary
| AB fundamental statistics | |
|---|---|
| Market cap | €53.56m |
| Earnings (TTM) | -€6.04m |
| Revenue (TTM) | €1.08m |
49.5x
P/S Ratio-8.9x
P/E RatioIs AB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AB income statement (TTM) | |
|---|---|
| Revenue | €1.08m |
| Cost of Revenue | €257.00k |
| Gross Profit | €825.00k |
| Other Expenses | €6.87m |
| Earnings | -€6.04m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.093 |
| Gross Margin | 76.25% |
| Net Profit Margin | -558.50% |
| Debt/Equity Ratio | -73.6% |
How did AB perform over the long term?
See historical performance and comparison